Overview

RELIEF: Randomized Episodic Versus Long-Term Suppression Experience With Famciclovir

Status:
Completed
Trial end date:
2005-06-01
Target enrollment:
Participant gender:
Summary
This trial will assess whether RGH patients who have two recurrent episodes within a three month period would benefit from suppressive treatment and whether patients prefer episodic therapy or suppressive therapy for the treatment of their RGH.
Phase:
Phase 4
Details
Lead Sponsor:
Novartis
Treatments:
2-Aminopurine
Famciclovir